Total Atorvastatin Use Increased Following Lipitor Patent Loss

Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds as expected, among recently treated dyslipidemia patients, share of Pfizer’s branded Lipitor declined from the third quarter of 2011 to the fourth quarter, as the drug lost patent protection.

Leave a Reply

Your email address will not be published.